McKesson Company (NYSE:MCK) – McKesson Posts Higher Than Anticipated Q2 Earnings; Raises FY22 EPS Outlook Once more

  • McKesson Corp (NYSE: MCK) reported second-quarter FY22 adjusted EPS of $6.15, +28{b02bdf04de3f9bc06c998e855c65941e7d8f5cd012e86469a83340818e6b6d52} Y/Y, and simply beating the analyst consensus of $4.66.
  • Revenues elevated 9{b02bdf04de3f9bc06c998e855c65941e7d8f5cd012e86469a83340818e6b6d52} Y/Y to $66.57 billion, surpassing the consensus of $63.12 billion, pushed by development within the U.S. Pharmaceutical phase, primarily attributable to elevated specialty volumes and market development, partially offset by branded to generic conversions.
  • U.S. Pharmaceutical Phase revenues elevated 11{b02bdf04de3f9bc06c998e855c65941e7d8f5cd012e86469a83340818e6b6d52} to $53.4 billion.
  • Prescription Know-how Options Phase revenues elevated 40{b02bdf04de3f9bc06c998e855c65941e7d8f5cd012e86469a83340818e6b6d52} to $932 million, pushed by greater volumes of know-how and repair choices. 
  • Medical-Surgical Options revenues improved 23{b02bdf04de3f9bc06c998e855c65941e7d8f5cd012e86469a83340818e6b6d52} to $3.1 billion, pushed by elevated gross sales of COVID-19 exams and development within the main care enterprise.
  • Adjusted gross revenue margin remained nearly unchanged at 5{b02bdf04de3f9bc06c998e855c65941e7d8f5cd012e86469a83340818e6b6d52}.
  • Outlook: McKesson elevated FY22 adjusted EPS to $21.95 – $22.55 (consensus of $20.32) from earlier steerage of $19.80 – $20.40 to mirror sturdy working efficiency and elevated contribution from the U.S. authorities’s COVID-19 vaccine packages.
  • Steerage assumes $1.30 – $1.80 adjusted EPS associated to the U.S. authorities’s COVID-19 vaccine distribution, kitting, and storage packages and $0.50 – $0.75 pertaining to COVID-19 exams, impairments for private protecting tools & associated merchandise.
  • Worth Motion: MCK shares closed 0.10{b02bdf04de3f9bc06c998e855c65941e7d8f5cd012e86469a83340818e6b6d52} greater at $208.08 on Monday.

Source link